Payment overview · 2025
General Payments
$967.56
52 reported records · 19 companies
Healthcare provider profile · identity verified
James M. Smith, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEWNAN, GA · NPI 1053395129
Verified facts
What the public records show
CMS Open Payments records show James M. Smith, M.D. received $967.56 in general payments during 2025 across 52 reported records.
Novo Nordisk Inc accounted for 14.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 299 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.78 | 14.0% | 11 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $120.83 | 12.5% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $87.68 | 9.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $67.88 | 7.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.07 | 6.7% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $63.17 | 6.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $58.55 | 6.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.86 | 5.6% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $43.50 | 4.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.74 | 4.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $38.37 | 4.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.26 | 3.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.18 | 3.2% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $28.75 | 3.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.60 | 2.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.40 | 2.2% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.86 | 1.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.86 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.22 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $967.56 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $120.83 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $110.42 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $87.48 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $87.48 | 7 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $67.88 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $67.88 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $63.17 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $58.55 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.86 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.89 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.30 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.74 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.89 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.29 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $31.18 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $28.75 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 191 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 196 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 133 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 299 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
196 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
196 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
133 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
299 | 62 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
191 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
35 | 34 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1034 | 272 |
| Atorvastatin Calcium | Atorvastatin Calcium | 902 | 254 |
| Omeprazole | Omeprazole | 677 | 175 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 559 | 156 |
| Metformin Hcl | Metformin Hcl | 531 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 525 | 130 |
| Lisinopril | Lisinopril | 518 | 138 |
| Metoprolol Succinate | Metoprolol Succinate | 415 | 106 |
| Hydrochlorothiazide | Hydrochlorothiazide | 397 | 118 |
| Gabapentin | Gabapentin | 381 | 98 |
| Losartan Potassium | Losartan Potassium | 365 | 114 |
| Trazodone Hcl | Trazodone Hcl | 358 | 94 |
| Prednisone | Prednisone | 314 | 191 |
| Ozempic | Semaglutide | 299 | 62 |
| Sertraline Hcl | Sertraline Hcl | 242 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 226 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 215 | 58 |
| Jardiance | Empagliflozin | 196 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 193 | 55 |
| Eliquis | Apixaban | 191 | 43 |
| Doxycycline Hyclate | Doxycycline Hyclate | 184 | 131 |
| Carvedilol | Carvedilol | 181 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 174 | 46 |
| Allopurinol | Allopurinol | 173 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 169 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 167 | 54 |
| Simvastatin | Simvastatin | 167 | 46 |
| Potassium Chloride | Potassium Chloride | 163 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 46 |
| Ezetimibe | Ezetimibe | 156 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 26 |
| Donepezil Hcl | Donepezil Hcl | 142 | 31 |
| Labetalol Hcl | Labetalol Hcl | 141 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 48 |
| Mounjaro | Tirzepatide | 133 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 133 | 40 |
| Metformin Hcl Er | Metformin Hcl | 127 | 38 |
| Furosemide | Furosemide | 125 | 45 |
| Glimepiride | Glimepiride | 125 | 37 |
| Atenolol | Atenolol | 122 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 117 | 29 |
| Montelukast Sodium | Montelukast Sodium | 117 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 39 |
| Famotidine | Famotidine | 82 | 25 |
| Spironolactone | Spironolactone | 81 | 19 |
| Tramadol Hcl | Tramadol Hcl | 81 | 24 |
| Mirtazapine | Mirtazapine | 79 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 20 |
| Alendronate Sodium | Alendronate Sodium | 74 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 19 |
| Farxiga | Dapagliflozin Propanediol | 71 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 18 |
| Aripiprazole | Aripiprazole | 68 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 13 |
| Januvia | Sitagliptin Phosphate | 62 | 15 |
| Buspirone Hcl | Buspirone Hcl | 58 | 14 |
| Memantine Hcl | Memantine Hcl | 57 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 13 |
| Lorazepam | Lorazepam | 55 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 35 |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | 13 |
| Valacyclovir | Valacyclovir Hcl | 46 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 12 |
| Finasteride | Finasteride | 41 | 13 |
| Synthroid | Levothyroxine Sodium | 41 | 11 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 25 |
| Sucralfate | Sucralfate | 40 | 15 |
| Alprazolam | Alprazolam | 39 | 18 |
| Colesevelam Hcl | Colesevelam Hcl | 39 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 23 |
| Minoxidil | Minoxidil | 38 | suppressed |
| Colchicine | Colchicine | 37 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 14 |
| Mupirocin | Mupirocin | 35 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 34 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 11 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Klor-Con M10 | Potassium Chloride | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Meloxicam | Meloxicam | 29 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 26 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Novolog | Insulin Aspart | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $967.56 · 52 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, Auvelity, CREXONT, ELIQUIS, GEMTESA, INSPIRE, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, SAPIEN 3 Ultra RESILIA, SHINGRIX, SPRAVATO, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error